

# Obsah

Dopis úvodem .....	9
<b>Přehled nejvýznamnějších studií let 2002-2003</b>	
<b>Klinické studie publikované ve světové literatuře .....</b>	<b>11</b>
1 Intracoronary vs Intravenous Abciximab in Acute Coronary Syndromes .....	11
2 Abciximab in Patients Undergoing Stenting After Loading with High-Dose Clopidogrel .....	12
3 ACUTE 2 .....	13
4 ADVANCE .....	15
5 AFFIRM .....	16
6 ALIVE .....	18
7 ALLHAT .....	20
8 ALLHAT-LLT .....	23
9 AMI-SK .....	25
10 ANBP2 .....	27
11 APRICOT-2 .....	29
12 APPROACH .....	31
13 ARTS .....	32
14 ASCOT-LLA .....	33
15 ASPECT .....	35
16 ASPECT-2 .....	37
17 ASSENT Plus .....	39
18 AZACS .....	41
19 BHACAS (1 & 2) .....	42
20 BLOS .....	44
21 BREATHE-1 .....	45
22 CADILLAC .....	46
23 CAPTIM: .....	48
24 CART - 1 .....	50
25 COAST .....	52
26 COMET .....	54
27 COMPANION .....	56
28 CONVINCENCE: .....	57
29 COOPERATE .....	59
30 C-PORT .....	60
31 CREDO .....	61
32 Cutting Balloon Global Randomized Trial .....	64
33 DANAMI - 2 .....	66
34 DANSTENT .....	68
35 DAVID .....	70
36 DELIVER .....	72

37	DIRECT .....	73
38	Early Revascularization in 14-Day Survivors of Acute Myocardial Infarction .....	75
39	EARTH .....	76
40	ELATE .....	77
41	ELSA .....	79
42	ENCORE I .....	81
43	ENTIRE-TIMI-23 .....	83
45	EPHESUS .....	85
46	EPHESUS .....	87
47	ERAFT .....	89
48	ESPRIT .....	91
49	ESTEEM .....	92
50	EUROPA .....	94
51	Ezetimibe .....	96
52	Ezetimibe .....	98
54	Ezetimibe - Pravastatin .....	100
55	Ezetimibe - Simvastatin .....	102
56	FACIT .....	103
57	FLORIDA .....	104
58	GREACE .....	106
59	GUSTO IV .....	108
60	GUSTO IV Substudy .....	110
61	GUSTO V .....	112
62	HALT-MI .....	113
63	Heart Protection Study .....	115
64	Heart Protection Study .....	117
65	HERS II .....	119
66	HERS II .....	121
67	CHALLENGE .....	122
68	CHAMP .....	124
69	CHARM .....	125
70	INTERACT .....	129
71	INTRO AMI .....	131
72	INVEST .....	132
73	IONA .....	133
74	ISAR-STEREO-2 .....	134
75	LIDO .....	135
76	LIFE .....	137
77	LIFE .....	139
78	LIPS .....	141
79	MADIT II .....	143
80	MAGIC .....	144
81	METHRO II .....	146
82	MIRACLE .....	148
83	MIRACLE ICD .....	149
84	MOST .....	150

85	MOXCON .....	151
86	Niacin-ER/Lovastatin Combination for Hyperlipidemia .....	152
87	Nesiritid .....	154
88	OPTIMAAL .....	155
89	OPTIME-CHF .....	157
90	OVERTURE .....	158
91	PACIFIC .....	160
92	PAFAC .....	161
93	PARAGON B .....	162
94	PENTATHLON 2000 .....	163
95	PRAGUE-2 .....	165
96	PRECEDENT .....	167
97	PRESTO .....	168
98	PREVENT .....	170
99	PRIME .....	172
100	PROSPER .....	174
101	RAVEL .....	175
102	REPLACE-2 .....	176
103	RITA 3 .....	178
104	RITZ-4 .....	180
105	Rosuvastatin – Atorvastatin .....	181
106	Rosuvastatin vs Atorvastatin .....	182
107	Rosuvastatin vs Pravastatin and Simvastatin .....	184
108	RUSSLAN .....	186
109	SACRE .....	188
110	SCOPE .....	189
111	SIRIUS .....	191
112	SMILE-2 .....	193
113	SOS .....	194
114	SPORTIF II .....	196
115	SPORTIF III .....	197
116	SPORTIF V .....	199
117	STAF .....	201
118	STELLAR .....	202
119	The Swiss Heart Study .....	204
120	TAXUS II .....	206
121	TENISS .....	207
122	TETAMI .....	209
123	THRIVE III .....	210
124	TORIC .....	212
125	tPA in Cardiac Arrest .....	213
126	TPT .....	214
127	UKPACE .....	215
128	VALIANT .....	216
129	VINO .....	218
130	VMAC .....	220

131	Warfarin, aspirin or both after myocardial infarction .....	221
132	WHI .....	223
<b>Nejvýznamnější české a slovenské studie publikované v české odborné literatuře v letech 2002–2003 .....</b>		<b>224</b>
133	Angina Treatment Patterns (ATP) Survey .....	224
134	Dlouhodobá léčba statiny u pacientů s ischemickou chorobou srdeční po koronární angioplastice .....	226
135	FAT: Fenofibrate versus Atorvastatin Trial .....	227
136	Gp IIb/IIIa blokátory destiček u akutního infarktu myokardu léčeného primární koronární angioplastikou .....	228
137	Léčba hypertenze u diabetiků inhibitory angiotenzin konvertujícího enzymu trandolaprilem - multicentrická studie .....	229
138	Meta-analýza studií PRAGUE 1 + 2 .....	230
139	MORE: MOexipril a REgrese hypertrofie levé komory v kombináční léčbě ...	231
140	Nedostatky léčby srdečního selhání v Evropě. Zaostává klinická praxe za evropskými směnicemi? Zaostává Česká republika za Evropou? .....	234
141	Nemocní s nestabilní anginou pectoris - jaká byla skutečnost v českých a moravských nemocnicích v roce 2000 .....	235
142	Nemocniční průběh akutního infarktu myokardu v České republice .....	236
143	Porovnání léčby hypertenze a rizikového profilu hypertoniků v obecné populaci a na specializovaném pracovišti .....	238
144	Použití ACE inhibitorů a statinů v ambulanci praktického lékaře, internisty a kardiologa .....	241
145	Simvor v léčbě hyperlipoproteinemie .....	243
146	TIGER .....	244
147	Zhodnocení účinnosti a snášenlivosti rilmenidinu u pacientů s mírnou až středně těžkou hypertenzí .....	245
<b>Zkratky .....</b>		<b>247</b>
<b>Klinické studie publikované v letech 2002-2003 ve světové literatuře .....</b>		<b>249</b>
<b>Klinické studie publikované v letech 2002–2003 v české literatuře .....</b>		<b>254</b>
<b>Přehled nejvýznamnějších studií let 2002-2003 – abecední seznam .....</b>		<b>255</b>
<b>Jmenný rejstřík .....</b>		<b>260</b>
<b>Rejstřík farmak .....</b>		<b>268</b>
<b>Časopisy .....</b>		<b>272</b>



## Klinické studie publikované v letech 2002-2003 ve světové literatuře

Intracoronary vs Intravenous Abciximab in Acute Coronary Syndromes .....	11
Abciximab in Patients Undergoing Stenting After Loading with High-Dose Clopidogrel .....	12
ACUTE 2: Antithrombotic Combination using Tirofiban and Enoxaparin .....	13
ADVANCE: Additional Value of NIR Stents for Treatment of Long Coronary Lesions .....	15
AFFIRM: The Atrial Fibrillation Follow-up Investigation of Rhythm Management .....	16
ALIVE: Amiodarone vs Lidocaine in Prehospital Ventricular Fibrillation Evaluation .....	18
ALLHAT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial .....	20
ALLHAT-LLT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial - Lipid Lowering Trial .....	23
AMI-SK: Acute Myocardial Infarction Streptokinase .....	25
ANBP2: The Second Australian National Blood Pressure Study .....	27
APRICOT-2: Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis Trial-2 .....	29
APPROACH: Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease .....	31
ARTS - Arterial Revascularization Therapy Study .....	32
ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm .....	33
ASPECT: Asian Paclitaxel-Eluting Stent Clinical Trial .....	35
ASPECT-2: Antitrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 .....	37
ASSENT Plus: Assessment of the Safety and Efficacy of a New Thrombolytic Plus .....	39
AZACS - Azithromycin in Acute Coronary Syndrome .....	41
BHACAS (1 & 2): Beating Heart Against Cardioplegic Arrest Studies 1 & 2 .....	42
BLOS: The $\beta$ -Blocker Length of Stay .....	44
BREATHE-1 - Bosentan Randomized Trial of Endothelin Antagonist Therapy-1 .....	45
CADILLAC: Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications .....	46
CAPTIM: Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction .....	48
CART - 1: Canadian Antioxidant Restenosis Trial .....	50
COAST: Heparin-Coated Stents in Small Coronary Arteries Trial .....	52
COMET: The Carvedilol Or Metoprolol European Trial .....	54
COMPANION: Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure .....	56
CONVINCE: Controlled Onset Verapamil Investigation of Cardiovascular End Points .....	57

COOPERATE: Combination Treatment of Angiotensin-II Receptor Blocker And Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease .....	59
C-PORT: The Atlantic Cardiovascular Patient Outcomes Research Team .....	60
CREDO: Clopidogrel for the Reduction of Events During Observation .....	61
Cutting Balloon Global Randomized Trial .....	64
DANAMI - 2: The Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Coronary Angioplasty in Acute Myocardial Infarction .....	66
DANSTENT: The Danish Multicenter Stent Study .....	68
DAVID: Dual Chamber and VVI Implantable Defibrillator Trial .....	70
DELIVER: The RX ACHIEVE Drug-Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Lesions .....	72
DIRECT: Comparison of Direct Stenting vs Stenting with Predilation for the Treatment of Selected Coronary Narrowings .....	73
Early Revascularization in 14-Day Survivors of Acute Myocardial Infarction .....	75
EARTH (Preliminary Report): Endothelin A Receptor Antagonist Trial in Heart Failure .....	76
ELATE: The Extended Low-Intensity Anticoagulation for Thrombo-Embolism .....	77
ELSA: European Lacidipine Study on Atherosclerosis .....	79
ENCORE I: Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function .....	81
ENTIRE-TIMI-23: Enoxaparin and TNK-tPA With or Without GP IIb/IIIa Inhibitor as Reperfusion Strategy in ST Evaluation MI-Thrombolysis in Myocardial Infarction-23 .....	83
EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study .....	85
EPHESUS: European Pentasaccharide Hip Elective Surgery Study .....	87
ERAFT: European Rythmol/Rytmonorm Atrial Fibrillation Trial .....	89
ESPRIT: Esapent for Prevention of Restenosis Italian Study .....	91
ESTEEM: Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent Myocardial Damage .....	92
EUROPA: European Trial On Reduction Events with Perindopril in Stable Coronary Artery Disease .....	94
Ezetimibe .....	96
Ezetimibe - Atorvastatin .....	99
Ezetimibe - Pravastatin .....	100
Ezetimibe - Simvastatin .....	102
FACIT: Folate After Coronary Intervention Trial .....	103
FLORIDA: Fluvastatin on Risk Diminishment After Acute Myocardial Infarction ..	104
GREACE: Greak Atorvastatin and Coronary-heart-disease Evaluation .....	106
GUSTO IV: Global Use of Strategies to Open Occluded Coronary Arteries IV – Acute Coronary Syndrome (1-Year Follow-Up) .....	108
GUSTO IV Substudy: A Global Utilization of Strategies to Open Occluded Coronary Arteries .....	110

GUSTO V: Global Utilization of Strategies to Open Occluded Coronary Arteries V	112
HALT-MI: Hu23F2G Anti-Adhesion to Limit Cytotoxic Injury Following AMI	113
Heart Protection Study	115
HERS II: Heart and Estrogen/Progestin Replacement Substudy	119
HERS II: Heart and Estrogen/Progestin Replacement Study - follow-up	121
CHALLENGE: Comparison of Efficacy and Safety of Atorvastatin and Simvastatin in Patients with Dyslipidemia With and Without Coronary Heart Disease	122
CHAMP: Combination Chemotherapy and Mortality Prevention	124
CHARM: The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity	125
INTERACT: Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment	129
INTRO AMI: Integrilin and Low-Dose Thrombolysis in Acute Myocardial Infarction Study	131
INVEST: International Verapamil SR/Trandolapril Study	132
IONA: Impact of Nicorandil in Angina	133
ISAR-STEREO-2: Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome Trial	134
LIDO: Levosimendan Infusion Versus Dobutamine	135
LIFE: Losartan Intervention for End Point Reduction	137
LIFE (Diabetes Mellitus Substudy): Losartan Intervention for End Point Reduction	139
LIPS: The Lescol Intervention Prevention Study	141
MADIT II: Multicenter Automatic Defibrillator Implantation Trial-II	143
MAGIC: Magnesium in Coronaries	144
METHRO II: Melagatran for Thrombin Inhibition in Orthopaedic Surgery	146
MIRACLE: Multicenter InSync Randomized Clinical Evaluation	148
MIRACLE ICD: Multicenter InSync ICD Randomized Clinical Evaluation	149
MOST: Mode Selection Trial in Sinus-Node Dysfunction	150
MOXCON: Moxonidine Congestive Heart Failure Trial	151
Niacin-ER/Lovastatin Combination for Hyperlipidemia	152
Nesiritid	154
OPTIMAAL: Optimal Trial In Myocardial Infarction with the Angiotensin II Antagonist Losartan	155
OPTIME-CHF: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure	157
OVERTURE: Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events	158
PACIFIC: Prevention with a Combined Inhibitor and Folic Acid in Coronary Heart Disease	160
PAFAC: Prevention of Atrial Fibrillation After Cardioversion (Preliminary Report)	161
PARAGON B: Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network B	162
PENTATHLON 2000: Fondaparinux vs Enoxaparin for Prevention of Venous	

Thromboembolism After Hip-Replacement Surgery .....	163
PRAGUE-2: Primary Angioplasty in Patients Transported from General Community Hospital to Specialized PTCA Units with or Without Emergency Thrombolysis-2 ...	165
PRECEDENT: The Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natreacor Therapy .....	167
PRESTO: Prevention of Restenosis with Tranilast and Its Outcomes .....	168
PREVENT: The Prevention of Recurrent Venous Thromboembolism .....	170
PRIME: Promotion of Reperfusion of Myocardial Infarction Evolution .....	172
PROSPER: Prospective Study of Pravastatin in the Elderly at Risk .....	174
RAVEL: Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions .....	175
REPLACE-2: Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events .....	176
RITA 3: Randomized Intervention Trial of Unstable Angina .....	178
RITZ-4: Randomized Intravenous Tezosentan Study-4 .....	180
Rosuvastatin - Atorvastatin .....	181
Rosuvastatin vs Atorvastatin .....	182
Rosuvastatin vs Pravastatin and Simvastatin .....	184
RUSSLAN: Randomized Study on Safety and Effectiveness of Levosimendan in Patients with Left Ventricular Failure Due to an Acute Myocardial Infarction ...	186
SACRE: Study Comparing Oral Anticoagulants with Reviparin .....	188
SCOPE: The Study on Cognition and Prognosis in the Elderly .....	189
SIRIUS : The Sirolimus-Eluting Baloon-Expandable Stent in the Treatment of Patients with de novo Native Coronary-Artery Lesions .....	191
SMILE-2: Survival of Myocardial Infarction Long-Term Evaluation-2 .....	193
SOS: Stent or Surgery .....	194
SPORTIF II: Stroke Prevention by Oral Thrombin Inhibitors in Atrial Fibrillation ...	196
SPORTIF III: Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation .....	197
SPORTIF V: Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation V .....	199
STAF: The Strategies of Treatment of Atrial Fibrillation .....	201
STELLAR: Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin .....	202
The Swiss Heart Study .....	204
TAXUS II: Paclitaxel-Eluting Stent Study .....	206
TENISS: The Tenax vs NIR Stent Study .....	207
TETAMI: Treatment with Enoxaparin and Tirofiban in Acute Myocardial Infarction	209
THRIVE III: Thrombin Inhibitor in Venous Thromboembolism .....	210
TORIC: Torasemide in Congestive Heart Failure .....	212
tPA in Cardiac Arrest .....	213
TPT: Thrombosis Prevention Trial .....	214



---

UKPACE: United Kingdom Pacing and Cardiovascular Events Trial .....	215
VALIANT: Valsartan in Acute Myocardial Infarction .....	216
VINO: Value of First Day Coronary Angiography/Angioplasty in Evolving Non-ST Segment Elevation Myocardial Infarction. An Open Multicenter Randomized trial ..	218
VMAC: Vasodilatation in the Management of Acute Congestive Heart Failure .....	220
Warfarin, aspirin or both after myocardial infarction .....	221
WHI: Women's Health Initiative .....	223

## Klinické studie publikované v letech 2002–2003 v české literatuře

Angina Treatment Patterns (ATP) Survey .....	224
Dlouhodobá léčba statiny u pacientů s ischemickou chorobou srdeční po koronární angioplastice .....	226
FAT: Fenofibrate versus Atorvastatin Trial .....	227
Gp IIb/IIIa blokátory destiček u akutního infarktu myokardu léčeného primární koronární angioplastikou .....	228
Léčba hypertenze u diabetiků inhibitory angiotenzin konvertujícího enzymu trandolapilem - multicentrická studie .....	229
Meta-analýza studií PRAGUE 1 + 2 .....	230
MORE: MOexipril a REgrese hypertrofie levé komory v kombinační léčbě .....	231
Nedostaty léčby srdečního selhání v Evropě. Zaostává klinická praxe za evropskými směrnici? Zaostává Česká republika za Evropou? .....	234
Nemocní s nestabilní anginou pectoris - jaká byla skutečnost v českých a moravských nemocnicích v roce 2000 .....	235
Nemocniční průběh akutního infarktu myokardu v České republice .....	236
Porovnání léčby hypertenze a rizikového profilu hypertoniků v obecné populaci a na specializovaném pracovišti .....	238
Použití ACE inhibitorů a statinů v ambulanci praktického lékaře, internisty a kardiologa .....	241
Šimvor v léčbě hyperlipoproteinemie .....	243
TIGER .....	244
Zhodnocení účinnosti a snášenlivosti rilmenidinu u pacientů s mírnou až středně těžkou hypertenzí .....	245